Gout management in Swiss primary care – a retrospective observational study

Meier Rahel, Di Gangi Stefania, Valeri Fabio, Rosemann Thomas, Zechmann Stefan, and the FIRE study group

Institute of Primary Care, University of Zurich and University Hospital Zurich, Switzerland

Summary

BACKGROUND: Gout is the most common form of inflammatory arthritis worldwide and its prevalence is rising. In Switzerland, there are no data available on the characteristics and treatment of gout patients. In this study, we aimed to describe numbers of patients affected by gout and hyperuricaemia and unveil approaches Swiss primary care physicians (PCPs) use for the management.

METHODS: This was a retrospective observational study using electronic medical routine data provided from 242 Swiss PCPs. Included were all their patients receiving urate-lowering therapy (ULT), with a diagnostic code for gout or who had a serum uric acid (SUA) measurement. According to their disease status, patients were classified into four subgroups (normal urate, hyperuricaemia, untreated gout, treated gout). For treatment analysis, patients with SUA measurements before and after ULT initiation were included. Comorbidities and risk factors for secondary causes relevant in the context of gout were collected. Outcomes were prevalence of gout and hyperuricaemia, characteristics of patients according to subgroup, number of SUA measurements, levels of SUA and patients who reached the treatment goal of a SUA level <360 μmol/l.

RESULTS: We assessed 15,808 patients and classified them into the subgroups. This yielded a prevalence of 1.0% for gout and 1.2% for hyperuricaemia. 2642 patients were diagnosed with gout of whom 2420 (91.6%) received urate-lowering therapy (ULT), with a diagnostic code for gout or who had a serum uric acid (SUA) measurement. Overall; 41.3% of patients with a gout treatment had at least one SUA measurement; 15.0% of patients with treated gout had a record of SUA measurements before and after ULT initiation; and 57.5% reached the treatment goal of <360 μmol/l after allopurinol treatment.

CONCLUSION: Swiss gout patients received comprehensive treatment, which is reflected in a high number of patients treated with ULT, laboratory tests per person and a high treatment success rate, although there is no systematic approach to the treatment of gout.

Keywords: gout, hyperuricaemia, urate lowering therapy, variety of care, electronic medical routine data

Introduction

Gout is the most common form of inflammatory arthritis worldwide and its prevalence is rising. The highest prevalence has been reported in occidental countries and among oceanic populations, affecting up to 7.6% of the population, which is a doubling in occidental countries in the last 15 years [1–7]. Similar in its clinical appearance to gout, hyperuricaemia is reported to be rising with a reported prevalence of up to 21.4% [4–6, 8]. In contrast to gout, which is diagnosed clinically, the diagnosis of hyperuricaemia is solely defined by serum uric acid (SUA) levels above 400 μmol/l (6.8 mg/dl) [7, 9–11].

There is international evidence that the management of these non-communicable entities varies widely. Previous studies investigating primary care populations in different occidental countries reported that 9–74% of all patients diagnosed with gout had SUA measurements, and 40–84.5% of all patients were treated with urate-lowering therapy (ULT) [3, 12–17]. Among treated patients, 21–50% reached the treatment target of <360 μmol/l (<6 mg/dl) recommended in most guidelines [18–20]. A recent Swiss guideline is in concordance with the international guidelines and recommends the treatment target of <360 μmol/l for gout patients, whereas it is not recommended to treat hyperuricaemia [21]. However, data on prevalence and the actual management of gout and hyperuricaemia in primary care is lacking for Switzerland.

Therefore, the aims of this study were:

– To investigate numbers and prevalence of patients affected by gout or hyperuricaemia to describe population characteristics and to assess differences in subpopulations

– To describe approaches Swiss primary care physicians (PCPs) used for the management of gout and to assess if the treatment goal (SUA level ≤ 360 μmol/l) was reached and which factors were associated with doing so.

Methods

Study design and setting

We conducted a retrospective observational database analysis based on the FIRE (family medicine International
Classification of Primary Care [ICPC] research using electronic medical records database, which was established in 2009 [22]. The FIRE database is a continuous collection of structured medical routine data from Swiss primary care practices. Until August 2019, more than 540 PCPs (approximately 10% of general practitioners working in the German-speaking region of Switzerland [23]) from more than 180 practices participated on a voluntary basis. This resulted in records from more 600,000 patients and more than 7 million consultations. In brief, the database covers patient demographics, vital signs, laboratory data, prescribed medication according to anatomical therapeutic chemical (ATC) coding and diagnoses based on ICPC Version 2 [24, 25]. For this analysis, data from 1 January 2009 to 31 August 2018 were included. According to the Local Ethics Committee of the Canton of Zurich, the project did not fall under the scope of the law on human research [26] and therefore no ethical consent was necessary (BASEC-Nr: Req-2017-00797).

Eligibility and inclusion criteria
Practices were eligible if they provided SUA measurements for FIRE. Within these practices, all patients alive and aged between 18 and 90 were included if one of the following criteria were fulfilled: (a) at least one prescription of ULT (ATC code M04); (b) ICPC code of gout (T92); (c) at least one SUA measurement.

Patient subgroups
The following subgroups were defined for further assessments of patient characteristic: normal urate (first SUA level <400 µmol/l, no ULT, no ICPC T92), hyperuricaemia (first SUA level >400 µmol/l, no ULT, no ICPC T92), untreated gout (ICPC T92, no ULT) and treated gout (ICPC T92, use of a ULT). For the analysis of the disease management, treated gout patients with available SUA measurements before and after treatment initiation were analysed according to their received treatment (allopurinol: ATC M04AA01; febuxostat: ATC M04AA03) and sex. The patient selection process is visualised in the study flowchart (fig. 1).

Database query and variables
From the FIRE database, we retrieved the following information at PCP level: age, sex, practice location (urban vs rural [27]) and practice type (single vs group practice). At patient level we retrieved: (a) demographic data (age, sex and body mass index [BMI]); (b) treatment data (number of SUA measurements, level of SUA measurements, type of medication); (c) information about comorbidities (alcohol abuse, obesity, hypertension, diabetes mellitus, dyslipidaemia, cardiovascular disease); and risk factors influencing SUA levels by increasing SUA production (psoriasis, high cell turnover diseases, cytotoxic chemotherapeutics) or by decreasing excretion (chronic kidney disease [CKD] stage 3a and higher, congestive heart failure, diuretics, laxatives) [28, 29]. Comorbidities and risk factors were defined using ICPC codes, laboratory measurements and ATC-codes (for detailed identification schemes see supplementary tables S1 and S2 in appendix 1) [30, 31].

Statistical analysis
We described patient level categorical data as numbers and proportions (n, %) and patient level continuous data as means and standard deviations (SDs). The percentage of missing observations was reported when necessary. To compare patient characteristics between patient subgroups, we used the chi-squared test for categorical variables and the analysis of variance (ANOVA) test for continuous variables. When testing difference in means or proportions between two groups, we reported results as 95% confidence intervals (CIs). A logistic multivariable mixed model, correcting for sex and repeated measurements (nested random effects: PCPs/patients) was used to examine treatment success. We specified the model as follows:

\[
\text{SUA level} \leq 360 \text{ µmol/l} \sim \text{fixed effects (X) + random effects of intercept (PCPs/patients)}
\]

where \(X\) = treatment indicator, sex.

We represented the results of the model as odds ratios (ORs) with 95% CI. The observations with missing values were excluded for regression analysis, but still included in the descriptive analysis. A p-value ≤0.05 was considered statistically significant. All statistical analyses were carried out using the R statistical package [32].

Results

Population characteristics
Within the FIRE network, 97 distinct practices with 242 PCPs covered 15,808 eligible patients (fig. 1). The PCPs’ mean age was 51.7 years (SD 10.4), 148 (61.2%) were male, 219 (90.5%) worked in a double or group practice and 130 (53.7%) practiced in an urban area. At the patient level, 15,808 patients met the inclusion criteria. Their mean age was 58.9 years (SD 16.2) and 8,840 (55.9%) were male; 49.1% (n = 7764) of the patient population had at least two comorbidities of which dyslipidaemia (n = 10,569, 66.9%), hypertension (n = 8990, 56.9%) and diabetes (n = 1704, 10.8%) were the most prevalent. We identified 4672 (29.6%) patients having risk factors for secondary causes of which the three most common were the use of diuretics (n = 3266, 20.7%), CKD stage 3a or higher (n = 2066, 13.1%) and the use of laxatives (n = 1187, 7.5%).

Subgroup classification revealed that 5773 (36.5%) of all eligible patients were affected by hyperuricaemia or gout, which resulted in a prevalence of 1.0% for gout and 1.2% for hyperuricaemia. All patient characteristics differed statistically significantly between the four different subgroups (table 1).

Disease management

SUA measurements
Overall, 22,169 SUA measurements were available. The mean number of SUA measurements per patient was 1.4 (SD 1.3) and mean SUA level was 339.4 µmol/l (SD 89.6). The SUA level was significantly higher among men (376.7 µmol/l, SD 89.6) than women (296.3 µmol/l, SD 89.3) with a 95% CI for the difference of −83.3 to −77.4 µmol/l. Moreover, SUA level rose with CKD grade. The number and the level of SUA measurements differed significantly.
between patient subgroups (table 1). Among the gout patients (treated and untreated), 1090 patients (41.3%) had at least one SUA measurement. Of the treated gout patients 364 (15.0%) had at least one SUA measurement before and after ULT initiation and were therefore eligible for the treatment effect analysis.

**Treatment**

Of all patients affected with gout, 2,420 (91.6%) were treated. The proportion of treated patients did not differ significantly between the sexes (1832, 91.4% of men and 588, 92.2% of women, p = 0.610 with a 95% CI for the difference of –0.02 to 0.03). Treatment with allopurinol led to a statistically significant average drop in SUA level of 67 µmol/l (95% CI 53.8 to 79.5) (table 2). The drop was 77 µmol/l in women (95% CI 49.5 to 104.3 µmol/l) and 60 µmol/l in men (95% CI 46.2 to 75.0 µmol/l). The treatment goal of SUA ≤360 µmol/l was reached by 199 patients (57.5%), 69 female patients (68.3% of all treated women), and 130 male patients (53.1% of all treated men). The OR for achieving the treatment goal with treatment was 4.34, (p <0.001, 95% CI 3.15 to 6.08). Female patients were more likely to achieve the treatment goal: OR 2.36 (p <0.001, 95% CI 1.53 to 3.69).

Only 28 patients in our sample had SUA measurements before and after treatment initiation with febuxostat (table 3). Febuxostat led to a drop in SUA level, of 71 µmol/
To investigate the treatment pattern of PCPs, we assessed SUA measurements before and after initiating ULT. Figure 2 displays a random sample of patients treated with ULT. As can be seen, SUA measurements before and after ULT initiation show a high variation in absolute numbers as well as in time intervals before and after treatment started.

**Discussion**

Our data analysis of Swiss primary care patients yielded a low prevalence of gout and hyperuricaemia. However, within all those eligible, 35% of patients were affected by gout or hyperuricaemia and more than 50% of those affected by gout had risk factors for secondary causes. The majority (91.6%) of patients affected by gout received treatment, of whom the vast majority (97.4%) received allopurinol. The number of SUA measurements among indi-

### Table 1: Patient characteristics according to defined subgroups.

| Patient characteristics | Normal urate | Hyperuricaemia | Untreated gout | Treated gout | p-value |
|-------------------------|--------------|----------------|---------------|-------------|---------|
| Number of patients      | 10,035       | 3131           | 222           | 2420        |         |
| Age (years), mean (SD)  | 55.5 (16.0)  | 62.3 (15.6)    | 63.4 (15.6)   | 68.1 (13.0) | <0.001  |
| Sex male, n (%)         | 4411 (44.0)  | 2425 (77.5)    | 172 (77.5)    | 1832 (75.7) | <0.001  |
| BMI class, n (%)        | Normal weight | 17 (7.7)      | 236 (7.5)     | 69 (2.9)    | 1596 (15.9) | <0.001  |
|                         | Obese        | 50 (22.5)      | 485 (15.5)    | 302 (12.5)  | 748 (7.5) |
|                         | Overweight   | 44 (19.8)      | 542 (17.3)    | 263 (10.9)  | 1475 (14.7) |
|                         | Underweight  | 0 (0.0)        | 12 (0.4)      | 9 (0.4)     | 286 (2.9) |
| Number of chronic diseases, mean (SD) | 1.33 (0.95) | 1.75 (1.01)    | 2.08 (1.53)   | 2.04 (1.21) | <0.001  |
| Risk factors and comorbidities, n (%) | Dyslipidaemia | 6901 (68.8) | 2284 (72.9) | 117 (52.7) | 1267 (52.4) | <0.001  |
|                          | Hypertension  | 4733 (47.2)   | 2111 (67.4)   | 158 (67.7)  | 1988 (82.4) | <0.001  |
|                          | Diabetes      | 662 (6.6)     | 411 (13.1)    | 47 (21.1)   | 584 (24.1) |
|                          | Cardiovascular disease | 270 (2.7) | 191 (6.1) | 48 (21.6) | 200 (8.3) |
|                          | Risk factors  | 1674 (18.7)   | 1100 (35.1)   | 111 (50)    | 1587 (65.6) | <0.001  |
|                          | Diuretics     | 1092 (10.9)   | 891 (28.5)    | 66 (29.7)   | 1217 (50.3) | <0.001  |
|                          | CKD           | 664 (6.8)     | 751 (23.9)    | 49 (22.1)   | 582 (24.0) |
|                          | Laxatives     | 640 (6.4)     | 240 (7.7)     | 19 (8.6)    | 288 (11.9) |
|                          | SUA level     | 1.37 (0.91)   | 1.79 (1.46)   | 0.62 (0.91) | 1.10 (1.2) |
|                          |             | 293.5 (80.3)  | 458.1 (67.9)  | 439.3 (112.5) | 419.0 (111.6) | <0.001  |
| Treatment, n (%)         | Allopurinol   | 0 (0.0)       | 0 (0.0)       | 0 (0.0)     | 2.357 (97.4) |
|                          | Febuxostat    | 0 (0.0)       | 0 (0.0)       | 0 (0.0)     | 91 (3.8) |
|                          | Probencid     | 0 (0.0)       | 0 (0.0)       | 0 (0.0)     | 13 (0.5) |

**BMI** = body mass index; **CKD** = chronic kidney disease 3b or higher; **SD** = standard deviation; **SUA** = serum uric acid * Percentages were calculated including missing values. Missing were: BMI 61.2%, SUA levels 9.8%. Reported p-values result from chi-square test (categorical variables) or ANOVA test (continuous variables). BMI classes are: underweight = BMI <20 kg/m²; normal weight = BMI ≥20 and <25 kg/m²; overweight = BMI ≥25 and < 30 kg/m²; obese = BMI ≥30 kg/m²

### Table 2: Treatment effect of allopurinol.

| Patients (n) | SUA measurements (n) | SUA levels (µmol/l) | SUA S360 µmol (%) |
|--------------|----------------------|---------------------|------------------|
| Total        | Before 346           | 581                 | 480              | 21.7%  |
|              | After 346             | 933                 | 431              | 57.5%  |
| Male         | Before 245            | 434                 | 485              | 19.6%  |
|              | After 245             | 651                 | 425              | 53.1%  |
| Female       | Before 101            | 147                 | 463              | 26.7%  |
|              | After 101             | 282                 | 386              | 68.3%  |

**SD** = standard deviation; **SUA** = serum uric acid

### Table 3: Treatment effect of febuxostat.

| Patients (n) | SUA measurements (n) | SUA levels (µmol/l) | SUA S360 µmol (%) |
|--------------|----------------------|---------------------|------------------|
| Total        | Before 28            | 69                  | 525              | 14.3%  |
|              | After 28             | 85                  | 454              | 67.9%  |
| Male         | Before 21            | 50                  | 504              | 9.5%   |
|              | After 21             | 50                  | 392              | 66.7%  |
| Female       | Before 7             | 19                  | 579              | 28.6%  |
|              | After 7              | 35                  | 543              | 71.4%  |

**SD** = standard deviation; **SUA** = serum uric acid
individual patients varied widely, indicating that most PCPs do not have a systematic approach to hyperuricaemia or gout. In recent studies, the prevalence of gout varied widely and was conflated to the range of 1–4% by Kuo et al. 2015. In studies reporting the prevalence of both, the prevalence of hyperuricaemia was three to five times higher than the prevalence of gout [4–6]. Our study reported a gout prevalence on the lower end of the range found in literature. Interestingly, survey data resulted generally in a rather higher gout prevalence than results from administrative or patient record data, which supports the validity of our data for gout [3, 4, 6, 12]. In contrast, the prevalence of hyperuricaemia reported in our study is much lower and suggests a large underestimation in our data [33]. This is mainly explained by the absence of a systematic screening within our “real world” primary care study population – which is not recommended by any guideline and benefit of which has not yet been studied [34, 35]. With regard to comorbidities and risk factors for secondary gout and hyperuricaemia, our results are comparable to the prevalence and proportions reported in previous studies [3, 6, 16].

Treatment rate of gout patients with ULT ranged among the highest ever reported; similarly high treatment rates were only documented in Germany (84.5%) and France (83%) [3, 14], where for many other countries, for instance the United Kingdom, the United States or Australia, treatment rates of 34%, 40% or 57% were reported [12, 15, 17, 36]. Moreover, besides the treatment rate, treatment success in patients who recorded a SUA before and after treatment initiation with allopurinol was achieved in 36% of cases, and was among the highest reported rates so far in primary care populations (21–40.9%) [12, 14, 15, 17, 36]. Treatment success in patients receiving with febuxostat was even higher, but owing to the small sample size, the result might not be very robust. The regression analysis revealed that female patients were more likely to achieve the treatment goal than male patients. This might be partially because female patients started with a lower SUA level than male patients, but it is also known that female patients are generally more closely monitored than male patients [37]. In general, the high treatment success rates in our sample might be influenced by the subgroup identification, which selected the patients most closely monitored. The high variability in the number of SUA measurements among individual patients and treatment patterns is in line with previous observational studies (9–79% of those diagnosed with gout had at least one SUA measurement) [3, 12, 36]. This high variability persisted, regardless of sex, treatment status and after correction for PCP as a cluster. Even among the subgroup of patients receiving ULT, a uniform and systematic approach via frequent SUA measurements, reflecting monitoring as it is established in many other chronic diseases, could not be detected. Obviously, gout does not receive the same awareness as, for instance, diabetes, and considerable gaps in disease knowledge and education among PCPs and patients exist [38].

Strengths and limitations
There are a number of limitations that should be considered when interpreting the results of our study. An important limitation of this study is missing information from electronic medical record as we could only assess structured data entries. Data entries such as free text diagnoses are lost. We would like to point out that we cannot exclude the possibility of misclassification within different patient subgroups as the definition of untreated gout was based solely on ICPC2-codes, which were not systematically provided by all PCPs. Therefore, the number of untreated gout cases might be underestimated, which also influences the reported prevalence for gout. The reported prevalence for hyperuricaemia must be considered with caution, as systematic hyperuricaemia screening is lacking in Swiss
primary care and only patients who had a SUA measurement at their PCP’s practice could be covered. Further, information on the dosage was not systematically available within our data and hence we could not address treatment aspects concerning the dosage.

On the other hand, our study has some important strengths. First, our sample of PCPs is representative of the Swiss PCP community in terms of gender, but slightly over-represents younger PCPs, PCPs working in group practices in urban settings [23]. Further, the validity of laboratory data is high since they are directly imported from the laboratory machines. Similarly, prescribed drugs are digitally recorded and effectively reflect PCPs’ real-life treatment of gout. To our knowledge, we are the first to examine the situation of gout and hyperuricemia in Switzerland and how patients are treated in the Swiss primary care setting.

Conclusion

Swiss gout patients received comprehensive treatment, which is reflected in a high number of patients treated with ULT, laboratory tests per person and a high treatment success rate, although there is no systematic approach to the treatment of gout. As gout and hyperuricemia are among the fastest rising non-communicable diseases, affecting the quality of life of patients tremendously, awareness and knowledge of the need for a systematic approach to patient treatment should be increased.

Acknowledgments

We thank the FIRE study group of primary care physicians for contributing to the present study.

Disclosure statement

The institute of primary care received an unrestricted grant from Menarini AG. The author(s) declared no other potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Data sharing statement

The data are gathered within the ongoing FIRE project. Additional data that are regularly gathered are stored in the FIRE database. The FIRE database can be accessed at any time by the scientific team of the institute. For external requests, access has to be requested from the head of the institute.

References

1. Winnard D, Wright C, Taylor WJ, Jackson G, Te Karu L, Gow PJ, et al. National prevalence of gout derived from administrative health data in Aotearoa New Zealand. Rheumatology (Oxford). 2012;51(8):981–9.
2. Wijndaele JM, Vliegbouwer W, Thevissen K, Arts IC, Dagnelie PC, Stehouwer CD, et al. Determinants of the prevalence of gout in the general population: a systematic review and meta-regression. Eur J Epidemiol. 2015;30(1):19–33. doi: https://doi.org/10.1007/s10654-014-9927-y.
3. Annemans L, Snaepen E, Gaskin M, Bonnaire M, Malier V, Gilbert T, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis. 2008;67(7):960–6. doi: https://doi.org/10.1136/ard.2007.076232.
4. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63(10):3136–41. doi: https://doi.org/10.1002/art.30520.
5. Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649–62. doi: https://doi.org/10.1038/nrrheum.2015.91.
6. Ting K, Gill TK, Keen H, Tucker GR, Hill CL. Prevalence and associations of gout and hyperuricemia: results from an Australian population-based study. Intern Med J. 2016;46(5):566–73. doi: https://doi.org/10.1111/imj.13006.
7. Pascut T, Liotta F. Gout: state of the art after a decade of developments. Rheumatology (Oxford). 2019;58(1):27–44. doi: https://doi.org/10.1093/rheumatology/kez053.
8. Kim Y, Kang J, Kim G-T. CR. Prevalence of hyperuricemia and its associated factors in the general Korean population: an analysis of a population-based nationally representative sample. Clin Rheumatol. 2018;37(9):2529–38. doi: https://doi.org/10.1007/s10067-018-3130-2.
9. Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol. 2014;26(2):186–91. doi: https://doi.org/10.1097/BOR.0000000000000028.
10. Shiozawa A, Szabo SM, Bolzani A, Cheung A, Choi HK. Serum Uric Acid and the Risk of Incident and Recurrent Gout: A Systematic Review. J Rheumatol. 2017;44(3):388–96. doi: https://doi.org/10.3899/jrheum.160452.
11. Richette P, Bardin T. Gout. Lancet. 2010;375(9711):318–28. doi: https://doi.org/10.1016/S0140-6736(09)68885-7.
12. Robinson PC, Taylor WJ, Dalbeth N. Gout: Prevalence and Quality of Care in a National Australian General Practice Population. J Rheumatol. 2015;42(9):1702–7. doi: https://doi.org/10.3899/jrheum.150110.
13. Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2015;74(4):661–7. doi: https://doi.org/10.1136/annrheumdis-2013-204463.
14. Maravic M, Hincapié N, Pilet S, Filipo R-M, Liotta F. Persistent clinical inertia in gout in 2014: An observational French longitudinal patient database study. Joint Bone Spine. 2018;85(8):314–5. doi: https://doi.org/10.1016/j.jbspin.2017.03.013.
15. Cotrell E, Crabtree V, Edwards JJ, Roddy E. Improvement in the management of gout is vital and overdue: an audit from a UK primary care medical practice. BMC Fam Pract. 2013;14(1):170. doi: https://doi.org/10.1186/1471-2296-14-170.
16. Jayaruban A, Larkins S, Soden M. Management of gout in general prac-
tice—a systematic review. Clin Rheumatol. 2013;34(9):1361–7. doi: https://doi.org/10.1007/s10067-014-2783-z.
17. Sarwares CW, Patel PS, Schumacher HR, Yang W, Brewster KK, Bakst AW. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol. 2006;12(2):61–5. doi: https://doi.org/10.1097/01.rhu.0000209882.50228.9f.
18. Khanna D, Fitzgerald JD, Khanna P, Bae S, Singh MK, Neogi T, et al.; American College of Rheumatology. American College of Rheumatology guidelines for management of gout. Part 1: systemic nonpharmacologic and pharmacologic therapeutic approaches to hyper-
uricemia. Arthritis Care Res (Hoboken). 2012;64(4):1431–46. doi: https://doi.org/10.1002/acr.21772.
19. Richette P, Doherty M, Pascual E, Barskova V, Becce F, Cañete-Alejandrab-Sanabria J, et al. 2016 updated EULAR evidence-based recommenda-
tions for the management of gout. Ann Rheum Dis. 2017;76(1):29–42. doi: https://doi.org/10.1136/annrheumdis-2016-209705.
20. Kiltz U, Alton R, Flock M, Krüger K, Manger B, Müller-Ladner U, et al. Langfassung zur S2k-Leitlinie Gichtarthritis (fachärztlich) [Full version of the S2k guidelines on gout arthritis - Evidence-based guidelines of the German Society of Rheumatology (DGRh)] Z Rheumatol. 2016;75(5/6):Suppl 2:1–60. German. doi: https://doi.org/10.1007/s00033-016-1417-6.
21. Wütrich H, Altmann F, So A. Guidelines for the treatment of gout: A Swiss perspective. Swiss Med Wkly. 2016;146:. doi: https://doi.org/10.4414/smw.2016.14341.
22. Chmiel C, Bhend H, Sens O, Zöller M, Rosemann T, FIRE study group. The FIRE project: a milestone for research in primary care in Switzerland. Swiss Med Wkly. 2011;140:.
23. Hostetter S, Kraft E. FMH-Ärztestatistik 2017 – aktuelle Zahlen. Schweiz Arzteztg. 2018;99(13–14):408–13. doi: https://doi.org/10.1044/saez.2018.0667.
24. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDS assignment, 21st edition. Oslo, Nor-
way: WHO Collaborating Centre for Drug Statistics Methodology; 2012.
25. World Organization of Family Doctors’ International Classification Committee. International Classification of Primary Care - ICPC-2. Oxford, UK: Oxford University Press; 2003.
26. Federal Act on Research involving Human Beings 2014 [cited 2019] Available from: https://www.admin.ch/opc/en/classified-compilation/20060131/index.html.
27. Raumliedungen. Federal Statistical Office; [cited 2019] Available from: https://www.bfs.admin.ch/bfs/de/home/grundlagen/raumliedungen.html.
28 Forster A, Krebs A. Die Gicht – lästig, aber behandelbar. Swiss Medical Forum – Schweizerisches Medizin-Forum. 2013;13(15):285–9.
29 Ben Salem C, Slim R, Fathallah N, Hmouda H. Drug-induced hyperuricaemia and gout. Rheumatology (Oxford). 2017;56(5):679–88. PubMed.
30 Lamers LM, van Vliet RC. The Pharmacy-based Cost Group model: validating and adjusting the classification of medications for chronic conditions to the Dutch situation. Health Policy. 2004;68(1):113–21. doi: http://dx.doi.org/10.1016/j.healthpol.2003.09.001. PubMed.
31 O’Halloran J, Miller GC, Britt H. Defining chronic conditions for primary care with ICPC-2. Fam Pract. 2004;21(4):381–6. doi: http://dx.doi.org/10.1093/fampra/cmh407. PubMed.
32 R Development Core Team. (2008). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org.
33 Kumar A U A, Browne LD, Li X, Adeeb F, Perez-Ruiz F, Fraser AD, et al. Temporal trends in hyperuricaemia in the Irish health system from 2006-2014: A cohort study. PLoS One. 2018;13(5):. doi: http://dx.doi.org/10.1371/journal.pone.0198197. PubMed.
34 Stamp L, Dalbeth N. Screening for hyperuricaemia and gout: a prospective and research agenda. Nat Rev Rheumatol. 2014;10(12):752–6. doi: http://dx.doi.org/10.1038/nrrheum.2014.139. PubMed.
35 Chales G. How should we manage asymptomatic hyperuricemia? Joint Bone Spine. 2019;86(4):437–43. doi: http://dx.doi.org/10.1016/j.jbspin.2018.10.004. PubMed.
36 Goossens J, Lancrenon S, Lanz S, Ea HK, Lambert C, Guggenbuhl P, et al. GOSEP 3: Management of gout by primary-care physicians and office-based rheumatologists in France in the early 21st century - comparison with 2006 EULAR Recommendations. Joint Bone Spine. 2017;84(4):447–53. doi: http://dx.doi.org/10.1016/j.jbspin.2017.04.002. PubMed.
37 Harrold LR, Yood RA, Mikuls TR, Andrade SF, Davis J, Fuller J, et al. Sex differences in gout epidemiology: evaluation and treatment. Ann Rheum Dis. 2006;65(10):1368–72. doi: http://dx.doi.org/10.1136/ard.2006.051649. PubMed.
38 Rai SK, Choi HK, Choi SHJ, Townsend AF, Shojania K, De Vera MA. Key barriers to gout care: a systematic review and thematic synthesis of qualitative studies. Rheumatology (Oxford). 2018;57(7):1282–92. doi: http://dx.doi.org/10.1093/rheumatology/kex530. PubMed.
### Appendix 1

**Table S1: Details of definitions to identify comorbidities.**

| Condition                  | Definition                                                                                     |
|----------------------------|-----------------------------------------------------------------------------------------------|
| Alcohol abuse              | ICPC-2 = 'P15|P16' OR ATC = 'N07BB01'                                                                      |
| Obesity                    | ICPC-2 = T83 OR BMI ≥25 and <30 THEN 'overweight'                                              |
|                            | ICPC-2 = T82 OR BMI ≥30 THEN 'obese'                                                          |
| Hypertension               | ICPC-2 = 'K8[5–7]' OR ATC = 'C02|C03A|C03EA01|C07|C08|C09A|C09B|C09C|C09D' OR ≥2 prescriptions in ≥6 months OR BDSYST ≥140 (at least twice) |
| Diabetes                   | ICPC-2 = (T89, T90) OR (ATC IN ['A10','ABX']) OR HbA1c ≥6.5%                                  |
| Dyslipidaemia              | ICPC-2 = T93 OR (ATC = [C10A AND ≥2 prescriptions in ≥6 months) OR triglyceride >1.7 mmol/l OR total-cholesterol >4.9 mmol/l OR LDL-cholesterol >3 mmol/l OR (sex = 'female' AND HDL-cholesterol ≤1.2 mmol/l) OR (sex = 'male' AND HDL-cholesterol ≤1 mmol/l) |
| Cardiovascular diseases    | ICPC-2 = 'K74|K75|K76|K77|K78|K79|F83|K89|K90|K91|K92'                                                                 |

**Table S2: Details of definitions to identify risk factors.**

| Condition                  | Definition                                                                                     |
|----------------------------|-----------------------------------------------------------------------------------------------|
| Psoriasis                  | ICPC-2 = 'S91'                                                                                  |
| Myeloma, lymphoma          | ICPC-2 = 'B7[2–4]'                                                                             |
| Solid tumours              | ICPC-2 = 'A79 | D7[4–8] | L71 | N74 | R8[4, 5] | X7[5–7] | Y77                                    |
| Cytotoxic therapy          | ATC = 'L04 | L01D | A12AA05 | C04AC | V06DC02 | C10AD | C10BA01 | C04AC01 | C10AD02 | C10AD52 | G04CB | G03FA05 | G03BA02 | G03EK01 | G03EA01 | G03BA03 | G03EA02 | A12AA06 | B05CA08 | D08AA01 | A12CC06 | B05XA15 |
| Decreasing serum uric acid excretion |                                                                             |
| Chronic kidney disease stage 3a and higher | GFR (CKD-EPI) <= 60 AND before OR after 30 days of inclusion                                           |
| Congestive heart failure   | ICPC-2 = 'K77'                                                                                  |
| Diuretics                  | ATC = 'C03 | C02L | C07C | C07D | C08G | C02LA | C02LB | C02LC | C02LE | C02LG | C02LK | C02LL | C02LN | C02LX | C07CA | C07CB | C07CG | C07DA | C07DB | C08GA | C09DA | C08GA02 | C07CB03|C07CB53 | C07DB01 | C09DA09 | C09BA07 | C02L07 | C07CA17 | C09DA06 | C09BA01 | C09BA08 | C02LC01 | C02LC51 | C02LA50 | C09BA12 | C02LA03 | C02LG01 | C02LG51 | C09BA02 | C09DA02 | C09DA10 | C09BA09 | C02LF01 | C02LG02 | C09DA04 | C07CG01 | C09BA03 | C09DA01 | C02LA04 | C02LB01 | C07CB02 | C09BA13 | C02LC05 | C09BA01 | C07CA02 | C02LL01 | C07CA23 | C09BA04 | C02LG03 | C02LG73 | C02LX01 | C07CA03 | C02LE01 | C09BA06 | C09BA05 | C02LA08 | C02LA02 | C02LA52 | C02LA01 | C02LA51 | C02LA71 | C02LA09 | C09DA07 | C07DA06 | C09DA03 | C07DA08 | C09DA03 | C02LK01 | C09BA15 |
| Laxatives                  | ATC = 'A06AD'                                                                                  |
| Ethambutol, pyrazinamide    | ATC = 'J04AK02|J04AK01'                                                                               |
| Aspirin                    | ATC = 'B01AC06'                                                                                |
| Levodopa                   | ATC = 'N04BA'                                                                                  |